期刊文献+

雷珠单抗联合光动力疗法治疗湿性年龄相关性黄斑变性患者

下载PDF
导出
摘要 目的:探讨分析雷珠单抗联合光动力疗法对湿性年龄相关性黄斑变性患者的疗效。方法:选取2017年11月~2018年11月收治的90例湿性年龄相关性黄斑变性患者为研究对象,随机分为对照组和研究组,每组45例。对照组给予光动力疗法,研究组在对照组的基础上给予雷珠单抗联合治疗,比较两组治疗效果。结果:两组治疗后黄斑中心凹厚度较治疗前降低,最佳矫正视力、a波振幅及b波振幅及均较治疗前升高,且研究组黄斑中心凹厚度、最佳矫正视力、a波振幅及b波振幅降低或升高幅度大于对照组,P<0.05;研究组血管内皮生长因子、血小板生长因子、内皮抑素水平均明显低于对照组,P<0.05;研究组在5%、10%、25%、100%对比度下敏感度均低于对照组,P<0.05;两组蛋白酶抑制剂-1水平比较无显著差异,P>0.05。结论:给予湿性年龄相关性黄斑变性患者雷珠单抗联合光动力疗法具有显著效果,可优化患者视觉功能,增强视觉敏感度,减少视网膜血管新生。
作者 马高恩 贺琳
出处 《实用中西医结合临床》 2019年第12期63-65,共3页 Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献8

二级参考文献122

  • 1缪天荣,缪晓平(整理),包廷钊,叶恬恬.《标准对数视力表》中的5分记录[J].眼视光学杂志,2005,7(4):217-219. 被引量:47
  • 2Krebs I,Véécsei Marlovits V,Bodenstorfer J,et al.Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration[J].Acta Ophthalmol,2013,91:e178-e183.
  • 3Williams PD,Callanan D,Solley W,et al.A prospective pilot study comparing combined intravitreal ranibizumab and halffluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration[J].Clin Ophthalmol,2012,6:1519-1525.
  • 4Larsen M,Schmidt-Erfurth U,Lanzetta P,et al.Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration[J].Ophthalmology,2012,119:992-1000.
  • 5Kaiser PK,Boyer DS,Cruess AF,et al.Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration[J].Ophthalmology,2012,119:1001-1010.
  • 6Bashshur ZF,Schakal AR,El-Mollayess GM,et al.Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration[J].Retina,2011,31:636-644.
  • 7Vallance JH,Johnson B,Majid MA,et al.A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration[J].Eye,2010,24:1561-1567.
  • 8Miller JW,Schmidt-Erfurth U,Sickenberg M,et al.Photodynamie therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration:results of a single treatment in phase 1 and 2 study[J].Arch Ophthalmol,1999,117:1161-1173.
  • 9Schmidt-Erfurth U,Miller JW,Sickenberg M,et al.Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related maeular degeneration:results of retreatments in a phase 1 and 2 stuy[J].Arch Ophthalmol,1999,117:1177-1187.
  • 10Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin:one-year results of 2 randomized clinical trials-TAP report 1.Treatment of age-related macular degeeration with photodynamic therapy (TAP) Study Group[J].Arch OphthatmoI,1999,117:1329-1345.

共引文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部